268 related articles for article (PubMed ID: 19149686)
1. Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.
Wong KK
Recent Pat Anticancer Drug Discov; 2009 Jan; 4(1):28-35. PubMed ID: 19149686
[TBL] [Abstract][Full Text] [Related]
2. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
[TBL] [Abstract][Full Text] [Related]
3. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.
Degirmenci U; Wang M; Hu J
Cells; 2020 Jan; 9(1):. PubMed ID: 31941155
[TBL] [Abstract][Full Text] [Related]
4. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
McCubrey JA; Milella M; Tafuri A; Martelli AM; Lunghi P; Bonati A; Cervello M; Lee JT; Steelman LS
Curr Opin Investig Drugs; 2008 Jun; 9(6):614-30. PubMed ID: 18516761
[TBL] [Abstract][Full Text] [Related]
6. Resistance to MEK inhibitors: should we co-target upstream?
Poulikakos PI; Solit DB
Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
[TBL] [Abstract][Full Text] [Related]
7. [Roles of targeting Ras/Raf/MEK/ERK signaling pathways in the treatment of esophageal carcinoma].
Chang YS; Liu JC; Fu HQ; Yu BT; Zou SB; Wu QC; Wan L
Yao Xue Xue Bao; 2013 May; 48(5):635-41. PubMed ID: 23888683
[TBL] [Abstract][Full Text] [Related]
8. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.
Chappell WH; Steelman LS; Long JM; Kempf RC; Abrams SL; Franklin RA; Bäsecke J; Stivala F; Donia M; Fagone P; Malaponte G; Mazzarino MC; Nicoletti F; Libra M; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Laidler P; Milella M; Tafuri A; Bonati A; Evangelisti C; Cocco L; Martelli AM; McCubrey JA
Oncotarget; 2011 Mar; 2(3):135-64. PubMed ID: 21411864
[TBL] [Abstract][Full Text] [Related]
9. ERK inhibition overcomes acquired resistance to MEK inhibitors.
Hatzivassiliou G; Liu B; O'Brien C; Spoerke JM; Hoeflich KP; Haverty PM; Soriano R; Forrest WF; Heldens S; Chen H; Toy K; Ha C; Zhou W; Song K; Friedman LS; Amler LC; Hampton GM; Moffat J; Belvin M; Lackner MR
Mol Cancer Ther; 2012 May; 11(5):1143-54. PubMed ID: 22402123
[TBL] [Abstract][Full Text] [Related]
10. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
12. [Focus on targeting the Ras-MAPK pathway: the Mek inhibitors].
Baldini C; Duchemann B; Hollebecque A; Routier É; Varga A; Gazzah A; Bahleda R; Besse B; Soria JC; Massard C
Bull Cancer; 2012 Sep; 99(9):865-74. PubMed ID: 25471668
[TBL] [Abstract][Full Text] [Related]
13. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
14. RAS/RAF/MEK inhibitors in oncology.
Rusconi P; Caiola E; Broggini M
Curr Med Chem; 2012; 19(8):1164-76. PubMed ID: 22257058
[TBL] [Abstract][Full Text] [Related]
15. Novel mitogen-activated protein kinase kinase inhibitors.
Chapman MS; Miner JN
Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
[TBL] [Abstract][Full Text] [Related]
16. MEK and RAF inhibitors for BRAF-mutated cancers.
Belden S; Flaherty KT
Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
[TBL] [Abstract][Full Text] [Related]
17. New perspectives on targeting RAF, MEK and ERK in melanoma.
Dumaz N; Lebbé C
Curr Opin Oncol; 2021 Mar; 33(2):120-126. PubMed ID: 33332926
[TBL] [Abstract][Full Text] [Related]
18. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.
Romerio F; Riva A; Zella D
Br J Cancer; 2000 Aug; 83(4):532-8. PubMed ID: 10945503
[TBL] [Abstract][Full Text] [Related]
20. Nobiletin induces inhibitions of Ras activity and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling to suppress cell proliferation in C6 rat glioma cells.
Aoki K; Yokosuka A; Mimaki Y; Fukunaga K; Yamakuni T
Biol Pharm Bull; 2013; 36(4):540-7. PubMed ID: 23546290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
